Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 160

Results For "C"

9148 News Found

Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


Gland Pharma receives approval for Acetaminophen Injection
Drug Approval | April 04, 2025

Gland Pharma receives approval for Acetaminophen Injection

The company expects to launch this product through its marketing partner in the near future


Sai Life Sciences sets up Peptide Research Center in India
News | April 04, 2025

Sai Life Sciences sets up Peptide Research Center in India

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates


SPARC announces submission of IND Application for SBO-154 to USFDA
News | April 04, 2025

SPARC announces submission of IND Application for SBO-154 to USFDA

The IND application supports the next phase of development of SBO-154


Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
News | April 04, 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study


Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
Biotech | April 04, 2025

Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development

This collaboration positions WACKER and RNAV8 as premium mRNA service providers


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Enhertu approved in EU in post-ET breast cancer
Drug Approval | April 04, 2025

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease


Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025
News | April 04, 2025

Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025

Awards highlight Avantor's commitment to the Biopharma industry